CAMBRIDGE-Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today the promotion of Robert Gallotto to chief business officer. This appointment reflects Alnara’s growing operations as the company prepares to submit a new drug application (NDA) and commercialize liprotamase, a novel, oral, porcine-free pancreatic enzyme replacement therapy (PERT) that has already completed a Phase 3 efficacy trial.
Mr. Gallotto brings to his new role over 20 years of pharmaceutical industry experience, with a focus on strategic planning, commercial and business development, and sales and marketing. Most recently, Mr. Gallotto held the position of senior vice president, operations and corporate development for the company. Prior to joining Alnara, he served as vice president of strategic planning, business and commercial development at Altus Pharmaceuticals, where he worked from 2001-2008. During his time at Altus, Mr. Gallotto was responsible for leading the company’s commercial strategy and strategic alliances, which included forging a pivotal partnership with the Cystic Fibrosis Foundation for liprotamase. Prior to joining Altus, he served as vice president of marketing and business development at Sage BioPharma and held several positions at Serono, Inc. and Biogen, Inc., where he was responsible for overall brand positioning, product launch planning, strategic planning and key alliance management for a portfolio of drugs including Gonal-F and Avonex.
“Bob has been instrumental in advancing Alnara’s business development strategy and his promotion to chief business officer is the result of his outstanding efforts since the company’s inception last year,” said Alexey Margolin, Ph.D., president and chief executive officer. “His leadership and commercial expertise will continue to enhance Alnara’s corporate presence and drive our efforts in developing and commercializing treatments for metabolic diseases. In particular, his experience in the development and implementation of product launch and marketing strategies will be invaluable as we seek FDA approval and prepare to launch and market liprotamase.”
“This is an exciting time for Alnara and I am pleased to be a part of the company’s expanded operations,” said Mr. Gallotto. “I strongly believe the company is poised to make a significant impact on patients with cystic fibrosis and chronic pancreatitis who have pancreatic insufficiency through our liprotamase program, and look forward to working with the rest of the team to advance the company’s business strategy and pipeline.”
No comments:
Post a Comment